10-QPeriod: Q2 FY2025

Medtronic plc Quarterly Report for Q2 Ended Oct 25, 2024

Filed November 26, 2024For Securities:MDT

Summary

Medtronic plc (MDT) reported strong financial results for the period ending October 25, 2024, showcasing a notable increase in both revenue and net income compared to the prior year. Net sales grew to $8.403 billion for the quarter and $16.318 billion for the six-month period, representing a 5% and 4% increase, respectively. Diluted earnings per share (EPS) rose significantly to $0.99 for the quarter and $1.79 for the six months, up from $0.68 and $1.28 in the prior year, respectively. This performance was driven by robust growth across key segments, including Cardiovascular, Neuroscience, and Diabetes, with specific product lines like the MiniMed 780G insulin pump system and structural heart devices showing particularly strong adoption. The company also demonstrated improved operational efficiency, with net cash provided by operating activities increasing to $1.944 billion for the six months ended October 25, 2024, contributing to a free cash flow of $1.020 billion. Medtronic successfully managed its debt, issuing €3.0 billion in Euro-denominated senior notes to enhance its financial flexibility, while continuing its share repurchase program. Despite some ongoing legal and regulatory matters, the company maintains a strong liquidity position and believes it is well-positioned to meet its operational needs and pursue strategic growth initiatives.

Financial Highlights

54 data points
Beta

Revenue

$8.40B

64.9% Gross Margin

Net Income

$1.28B

15.2% Net Margin

EPS (Diluted)

$0.99

Total Assets

$90.04B

Cash & Equivalents

$1.39B

Free Cash Flow

$554.00M

Financial Statements
Beta
Revenue$8.40B
Cost of Revenue$2.95B
Gross Profit$5.46B
SG&A Expenses$2.76B
Operating Income$1.59B
Net Income$1.28B
EPS (Basic)$0.99
EPS (Diluted)$0.99
Shares Outstanding (Basic)1.28B
Shares Outstanding (Diluted)1.29B

Key Highlights

  • 1Total net sales increased by 5% to $8.4 billion for the quarter and 4% to $16.3 billion for the six months, demonstrating consistent top-line growth.
  • 2Diluted EPS saw a significant improvement, rising to $0.99 for the quarter and $1.79 for the six months, indicating enhanced profitability.
  • 3The Cardiovascular segment reported a 6% sales increase for both the quarter and six months, driven by TAVR, Cardiac Rhythm Management, and Cardiac Surgery.
  • 4The Diabetes segment experienced strong growth with a 12% increase in net sales for both periods, largely due to the MiniMed 780G system adoption.
  • 5Net cash provided by operating activities increased to $1.94 billion for the six months, contributing to a robust free cash flow of $1.02 billion.
  • 6Medtronic successfully issued €3.0 billion in Euro-denominated senior notes, strengthening its liquidity and financial flexibility.
  • 7The company maintained strong credit ratings from S&P and Moody's, reflecting its sound financial health.

Frequently Asked Questions

Medtronic reported strong financial results, with total net sales increasing by 5% to $8.4 billion for the three months ended October 25, 2024, and by 4% to $16.3 billion for the six months ended October 25, 2024. Diluted earnings per share also saw a significant increase to $0.99 for the quarter and $1.79 for the six months. Operating cash flow improved substantially, and the company maintained a strong liquidity position.

Key segments driving revenue growth included Cardiovascular, which saw a 6% increase due to strong performance in TAVR, Cardiac Rhythm Management, and Cardiac Surgery. The Diabetes segment also showed robust growth with a 12% increase in net sales, primarily driven by the MiniMed 780G insulin pump system. The Neuroscience segment also contributed positively with a 7% increase in net sales for the quarter.

Medtronic successfully managed its financial resources by issuing €3.0 billion in Euro-denominated senior notes, which enhanced its liquidity. The company also generated $1.02 billion in free cash flow for the six months ended October 25, 2024, and continued its share repurchase program, demonstrating a commitment to returning value to shareholders while maintaining financial flexibility.

While Medtronic is involved in various legal and regulatory matters, including intellectual property, product liability, and tax disputes, the company's filings do not indicate any immediate material adverse impact from these issues. The company states it records liabilities when a loss is probable and reasonably estimable, and where no such accrual is made, it implies uncertainty regarding the probability or estimability of a loss. Investors should continue to monitor these ongoing matters.